Press Releases

WESANA HEALTH OUTLINES ACCELERATED DRUG DEVELOPMENT PATHWAY

CHICAGO and TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of…

read more
150 150 Wesana Health

Wesana Health CEO Daniel Carcillo to Speak at Several Leading Investor and Industry Events

CHICAGO and TORONTO, March 29, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel…

read more
150 150 Wesana Health

Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant

CHICAGO and TORONTO, March 22, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel…

read more
150 150 Wesana Health

Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013

Pre-IND Meeting is a Significant Milestone in the Clinical Development of SANA-013, Defining the Pathway to Initiate in-Human Clinical Trials in Q4 2022 CHICAGO and TORONTO, March 14, 2022 (GLOBE…

read more
150 150 Wesana Health

Wesana Provides Updates on Build-out of Third Clinic

Naperville clinic to open Spring 2022 CHICAGO and TORONTO, March 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc.  (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life…

read more
150 150 Wesana Health

Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol

Wesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol, significantly reduced…

read more
150 150 Wesana Health

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

The meeting is scheduled for March 11, 2022 CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc.  (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven…

read more
150 150 Wesana Health

Wesana Health Closes $4 Million Convertible Note Round

Funding to support Company's entrance into the psychedelics space New additions to senior management and leadership teams CHICAGO, Jan. 21, 2021 /PRNewswire/ -- Wesana Health, an emerging life sciences company committed to patient…

read more
150 150 Wesana Health
Start Typing